A Phase I/II Clinical Trial of Lenalidomide in Combination With Oral Cyclophosphamide in Patients With Previously Treated Hormone Refractory Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 14 Jun 2018
At a glance
- Drugs Cyclophosphamide (Primary) ; Lenalidomide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 07 May 2018 Status changed from active, no longer recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 29 Mar 2010 New trial record